{"id":838601,"date":"2025-04-17T08:55:37","date_gmt":"2025-04-17T12:55:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/"},"modified":"2025-04-17T08:55:37","modified_gmt":"2025-04-17T12:55:37","slug":"werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/","title":{"rendered":"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WATERTOWN, Mass., April  17, 2025  (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting.<\/p>\n<p align=\"justify\">\u201cSteve brings deep experience in strategic transactions to Werewolf at this critical time,\u201d said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. \u201cWerewolf is approaching important inflection points this year with interim dose expansion data from the WTX-124 Phase 1\/1b clinical trial expected to guide discussions with regulators on potential registrational pathways, and our PREDATOR platform continuing to develop novel molecules for oncology, immunology and additional therapeutic modalities.\u201d<\/p>\n<p align=\"justify\">Mr. Bloom joins Werewolf from Vincerx Pharma, Inc., where he served as Chief Business Officer. During his time at Vincerx as a member of the executive leadership team focused on business development, commercial assessment, and corporate strategy, Mr. Bloom led a program and platform valuation project and worked with the executive team on multiple transaction initiatives to help stabilize the company.\u00a0\u00a0 Previously, he worked at several biotechnology companies including Ziopharm Oncology, Inc., Verastem Oncology, and Vavotar Life Sciences LLC, where he led multiple business development transactions. Mr. Bloom also held senior roles at Eli Lilly and Company earlier in his career where he led sales and marketing, patient advocacy, and corporate affairs functions.<\/p>\n<p align=\"justify\">\u201cWerewolf is positioning itself to change the way cancer is treated through its novel immunotherapy technology designed to attack the tumor while minimizing patient side effects,\u201d said Mr. Bloom. \u201cWerewolf\u2019s lead program WTX-124 has demonstrated durable confirmed responses in patients with cancer, and Werewolf has continued to develop a deep and diverse pipeline using its PREDATOR technology. I am thrilled to join this experienced team and look forward to working with Werewolf to advance its products.\u201d<\/p>\n<p align=\"justify\">Mr. Bloom graduated from Northeastern University School of Pharmacy and has been an American Cancer Society Road to Recovery driver since 2008. Mr. Bloom is currently Chair of the Board of Directors of the CLL Society, a nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma community through patient education, advocacy, support, and research.<\/p>\n<p align=\"justify\">In connection with Mr. Bloom\u2019s appointment, Werewolf\u2019s board of directors approved a stock option grant to\u00a0Mr. Bloom as an inducement material to\u00a0his entering into employment with\u00a0Werewolf in accordance with Nasdaq Listing Rule 5635(c)(4).\u00a0The stock option provides for the purchase of up to 201,720 shares of\u00a0Werewolf\u00a0common stock at an exercise price equal to the closing price of the Werewolf common stock on May 1, 2025, the effective date of grant.\u00a0 The stock option has a ten-year term and vests as to 25% on the first anniversary of the effective date of Mr. Bloom\u2019s employment and the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service by Mr. Bloom to Werewolf or any of its subsidiaries through each applicable vesting date.<\/p>\n<p align=\"justify\">\n        <strong>About Werewolf Therapeutics:<\/strong><br \/>\n        <br \/>Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR<sup>\u00ae<\/sup>\u00a0platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf\u2019s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company\u2019s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4bEmOrhxNqBXRQVC3_qJUaS_nmcn1sOaakGIZMUBQZWibh8DITryA2V0w8rCQUobRsrHawVQWQlKVMaOxP94jAKpA-REFC_LlRBaSjAYcV4=\" rel=\"nofollow\" target=\"_blank\">www.werewolftx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf\u2019s strategy, future operations, prospects, plans, and objectives of management; the expected timeline for the preclinical and clinical development of product candidates and the availability of data from such preclinical and clinical development; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cdesigned to,\u201d \u201cengineered,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cobjective,\u201d \u201congoing,\u201d \u201cplan,\u201d \u201cpositioning itself to,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpromise,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cworking to,\u201d or \u201cwould,\u201d or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Company\u2019s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; as well as the risks and uncertainties identified in the \u201cRisk Factors\u201d section of the Company\u2019s most recent Form 10-K filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company\u2019s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p align=\"justify\">WEREWOLF<sup>\u00ae<\/sup>, the WEREWOLF logo, PREDATOR<sup>\u00ae<\/sup>, INDUKINE<sup>\u2122<\/sup>\u00a0and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong>\n      <\/p>\n<p>Dan Ferry<br \/>LifeSci Advisors<br \/>617.430.7576<br \/>daniel@lifesciadvisors.com<\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Amanda Sellers<br \/>Deerfield Group<br \/>301.332.5574<br \/>amanda.sellers@deerfieldgroup.com<\/p>\n<p>\n        <strong>Company Contact:<\/strong>\n      <\/p>\n<p>Timothy Trost<br \/>Chief Financial Officer<br \/>Werewolf Therapeutics<br \/>ttrost@werewolftx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDhhOTI1NGUtMTg1Yi00ZTZkLTk4ZDktYjMxZmUzNGNmYzA3LTEyMTkzMDAtMjAyNS0wNC0xNy1lbg==\/tiny\/Werewolf-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. \u201cSteve brings deep experience in strategic transactions to Werewolf at this critical time,\u201d said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. \u201cWerewolf is approaching important inflection points this year with interim dose expansion data &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-838601","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. \u201cSteve brings deep experience in strategic transactions to Werewolf at this critical time,\u201d said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. \u201cWerewolf is approaching important inflection points this year with interim dose expansion data &hellip; Continue reading &quot;Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-17T12:55:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer\",\"datePublished\":\"2025-04-17T12:55:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/\"},\"wordCount\":1198,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/\",\"name\":\"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=\",\"datePublished\":\"2025-04-17T12:55:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/","og_locale":"en_US","og_type":"article","og_title":"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - Market Newsdesk","og_description":"WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. \u201cSteve brings deep experience in strategic transactions to Werewolf at this critical time,\u201d said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. \u201cWerewolf is approaching important inflection points this year with interim dose expansion data &hellip; Continue reading \"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-17T12:55:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer","datePublished":"2025-04-17T12:55:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/"},"wordCount":1198,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/","name":"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=","datePublished":"2025-04-17T12:55:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzQwMiM2ODY5NTE4IzIyMDc3NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-appoints-steven-bloom-as-chief-business-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/838601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=838601"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/838601\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=838601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=838601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=838601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}